Best Practice in the Management of Concha Bullosa in FESS Operation
1 other identifier
interventional
62
1 country
1
Brief Summary
Concha bullosa (CB) refers to the condition where the middle turbinate's interior is aerated (making the turbinate wide and thick). CB can narrow the middle meatus and the ostiomeatal complex. In adults suffering from chronic sinusitis, the prevalence of CB is approximately 34%. The most common treatment method for CB is turbinate crushing. This is considered a conservative treatment that preserves the mucous membranes relatively intact without opening the interior of the turbinate. Another fairly common method is the removal of the lateral part of the bullous middle turbinate. Opening the CB and removing the lateral part of the middle turbinate can lead to adhesions between the middle turbinate and the lateral wall of the nose. These adhesions can impede airflow and narrow or completely close the ostium or the surgically created middle meatal antrostomy. Crushing the CB is technically easier and possibly a less traumatic procedure. However, it is suspected that some of these crushed bullous turbinates may refill. The development of a mucocele is another potential issue. Crushing might be a better option compared to resection in the long term. Preserving the mucous membranes during crushing may reduce the formation of adhesions, which are sometimes seen after resection of the middle turbinate. The purpose of the study is to investigate the long-term benefits and side effects of CB treatment methods. The study will include 60 patients undergoing a basic Functional Endoscopic Sinus Surgery (FESS) procedure due to recurrent or chronic maxillary sinusitis. The patients will be randomized, with 31 undergoing resection and 31 undergoing crushing. Before the procedure, patients will undergo a CT scan (NSO-TT) and symptom evaluation through various questionnaires. All patients will also undergo nasoscopy. One year after the procedure, the patients' conditions will be reassessed (questionnaires, nasoscopy, NSO-TT only if necessary), including the need for revision surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 21, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 12, 2023
CompletedFirst Submitted
Initial submission to the registry
November 12, 2024
CompletedFirst Posted
Study publicly available on registry
November 13, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedMarch 10, 2026
October 1, 2024
5.3 years
November 12, 2024
March 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
postoperative SNOT-22
postoperative SNOT-22 score
1 year
Secondary Outcomes (1)
LM endoscopy score
1 year
Other Outcomes (1)
Antibiotics usage postoperatively
1 year
Study Arms (2)
crushing
ACTIVE COMPARATORConcha bullosa crushing group
resection
ACTIVE COMPARATORConcha bullosa resection group
Interventions
Eligibility Criteria
You may qualify if:
- chronic or recurrent rhinosinusitis
- months of regular nasal corticosteroid usage
- No prior endoscopic procedures of the paranasal sinuses
- EPOS criteria for CRS are met: inflammation of the paranasal sinuses with at least 2 symptoms, one of which must be nasal obstruction/congestion or nasal discharge (anterior/posterior):
- facial pain/pressure in the facial area
- reduced or lost sense of smell SNOT-22 25 or higher
- Complications of CRS (e.g., mucocele)
- Pregnancy/breastfeeding or plans for them in the near future
- Coagulation disorders
- Systemic diseases: cystic fibrosis, primary ciliary dysfunction, sarcoidosis, Wegener's granulomatosis
- Immunosuppression: diagnosed SAD, CVI, HIV, or use of biological/immunosuppressive drugs
- Immunotherapy
- Daily use of systemic corticosteroids
- Communication issues (non-Finnish-speaking patient, neurological/psychiatric problems)
- SNOT-22 score \< 25
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Helsinki University Hospital Ear Clinic
Helsinki, Uusimaa, 00130, Finland
Related Publications (1)
Dogru H, Uygur K, Tuz M. Concha bullosa squeezer for turbinoplasty (Dogru forceps). J Otolaryngol. 2004 Apr;33(2):111-3. doi: 10.2310/7070.2004.02112. No abstract available.
PMID: 15518100BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Markus Lilja, PhD
Helsinki University Central Hospital
- PRINCIPAL INVESTIGATOR
Mario Järvekülg, MD
Helsinki University Central Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- specialist doctor
Study Record Dates
First Submitted
November 12, 2024
First Posted
November 13, 2024
Study Start
March 21, 2018
Primary Completion
July 12, 2023
Study Completion
December 31, 2025
Last Updated
March 10, 2026
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share
According to the data protection regulations, patients' personal data cannot be shared publicly in Finland.